GSK3A and Alzheimer disease: Specifically, enzyme activities of AKT1 (GSK3α/3β fusion protein phosphorylation by immunoprecipitated AKT1) in temporal cortex were significantly increased in patients with AD, compared with non-disease controls, and the activities were correlated with Braak staging for neurofibrillary changes [10].